ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

volrustomig

Also written as “Volrustomig”, “MEDI5752” and “AZD9592 + Volrustomig”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Squamous Cell Carcinoma of Head and Neck · Stomach Neoplasms · Carcinoma, Renal Cell, led by 2 companies.

Drug pageVolrustomig: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 2, 202319 company-led studies, 17 open or runningNext primary completion: Jan 29, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only1716 open or runningphase 3since Aug 2, 2023Mar 28, 2018Jan 29, 2027phase 1 · NCT07000149
Presage Biosciences21 open or runningearly phase 1since Sep 1, 2020Sep 1, 2020Dec 2031early phase 1 · NCT04541108
  • Named in AstraZeneca’s own pipeline as volrustomig, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Parexel, Daiichi Sankyo and Arcus Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Presage Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 1, 2020First study: early phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT04541108 · 15 enrolled · United States
  2. Jul 21, 2022Named volrustomigINNProposed as its International Nonproprietary Name in WHO's List 127 · before, MEDI5752
  3. Apr 3, 2024Early phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT06366451 · 17 enrolled · United States

Ahead

  1. Dec 2031Primary completion: early phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT04541108

TargetBeta

“An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CT…”NCIt, read by Claude
“An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

All 2 Presage Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06366451Squamous Cell Carcinoma of Head and Neck · United StatesEarly 1CompletedMar 25, 202617
NCT04541108Squamous Cell Carcinoma of Head and Neck · United StatesEarly 1Active, not recruitingDec 203115

How it is read

Names in the registry

  • “Volrustomig”, 14 entries
  • “MEDI5752”, 4 entries
  • “AZD9592 + Volrustomig”, 2 entries
  • “volrustomig”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.